Oncology
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
Surgical resection remains the most widely used curative approach for hepatocellular carcinoma (HCC), yet the postresection recurrence rate can be as high as 50%-70%. Numerous studies have explored adjuvant therapies for HCC, from the STORM trial in 2015 to the recent...
This Radiation Therapy Outperformed TACE in Liver Cancer
A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and progression-free survival than those who received transarterial chemoembolization...
Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial)
Adjuvant treatments specifically for resectable ECC and GBC patients are scare and adjuvant chemotherapy alone delivers limited efficacy. Immunotherapy and radiotherapy are potential effective treatments and both of them may synergize with chemotherapy. Learn...
Contrast-Enhanced Ultrasound May Improve LI-RADS Assessment of High-Risk Indeterminate Liver Lesions
Emerging research suggests that contrast-enhanced ultrasound (CEUS) may lead to more definitive detection of hepatocellular carcinoma (HCC) than magnetic resonance imaging (MRI) or computed tomography (CT). Learn More
What is Proton Therapy?
Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting. Learn More
The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors
Histotripsy is a nonthermal, nonionizing, noninvasive, focused US technique that relies on cavitation for mechanical tissue breakdown at the focal point. Preclinical data have shown its safety and technical success in the ablation of liver tumors. Learn More
Zanidatamab exhibits ‘promising’ efficacy in advanced HER2-positive biliary tract cancer
Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting. Learn More
About the TheraBionic P1 device
Dr. Boris Pasche, MD, PhD explains how the TheraBionic P1 medical device works to treat cancer. The TheraBionic P1 device is currently FDA approved for treatment of adult patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, for...
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Liver cancer is one of the most difficult solid tumors to treat and is responsible for one-third of cancer-related deaths worldwide. In particular, the quest for effective therapeutic strategies for hepatocellular carcinoma, which often arises from a chronic...
The association of metabolic syndrome score trajectory patterns with risk of all cancer types
Metabolic syndrome (MetS) elevates cancer risk. However, a single MetS assessment does not fully reveal the long-term association with cancer. Inflammation, alongside MetS, could synergistically expedite both the onset and advancement of cancer. This study aims to...
Pediatric Oncology
Hepatoblastoma
Hepatoblastomas are the most common primary malignant liver tumor in pediatric patients, and most often occur within the first 2 years of life. The histologic types are subdivided into the epithelial type and the mixed type. Over the last 3 decades, the treatment has...
Childhood Liver Cancer Treatment
Hepatoblastoma and hepatocellular carcinoma are treated differently. Both require complete surgical removal for treatment to be successful. Hepatoblastoma responds well to chemotherapy, but hepatocellular carcinoma tumors are usually treated with surgery alone. Learn...
Childhood Hepatocellular Carcinoma
Childhood hepatocellular carcinoma is a rare type of cancer that forms in liver cells called hepatocytes. Hepatocytes are the most common cells of the liver, and they carry out most of the functions of the liver. Learn More